Truist lowered the firm’s price target on Synovus (SNV) to $55 from $56 and keeps a Buy rating on the shares as part of a broader research note on Regional Banks, updating the firm’s models following their Q3 results. The firm is raising its estimates on higher revenue but revising its price target down pending the Pinnacle-Synovus deal closing in early 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNV: